This is an unprecedented time. It is the dedication of healthcare workers that will lead us through this crisis. Thank you for everything you do.
COVID-19 Resource Center

      Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Log In

    Show
    Forgot your password?
    Log In
    Or create a new account (it's free)

    Forgot Password?

    Enter your email address and we'll send you a link to reset your password.

    Get New Password

    Sign In Required

    To save favorites, you must log in.

    Creating an account is free, easy, and takes about 60 seconds.

    Attention COACH STUDY participants:

    The principal investigators of the study request that you use the official version of the modified score here.

    EUTOS Score for Chronic Myelogenous Leukemia (CML)

    Predicts outcomes after CML treatments, specifically adjusted for tyrosine kinase treatments.

    INSTRUCTIONS

    Use in newly-diagnosed patients before starting therapy.

    When to Use
    Pearls/Pitfalls
    Why Use

    Newly-diagnosed CML patients prior to discussions regarding prognosis and treatment options.

    • The EUTOS (European Treatment and Outcome Study) Score predicts survival and can also be used to predict the probability of complete cytogenetic response at 18 months.
    • Has better predictive value than the Sokal Score.
    • Spleen size estimation is subjective; however, that subjectivity is also included in other CML prognostic scores.
    • Developed in patients treated with imatinib, so outcomes may not apply with newer generation therapies.
    • Estimates response to therapy to, and survival on, the reference TKI (tyrosine kinase inhibitor) imatinib.
    • Only requires two values, which can be clinically detected prior to completing a bone marrow biopsy.
    cm
    %

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights
    Dr. Joerg Hasford

    About the Creator

    Joerg Hasford, MD, PhD, is a Professor of Medical Data Processing, Biometrics and Epidemiology at the University of Munich in Germany. He is the chairman of the Ethics Committee of the Bavarian Medical Association and the Working Group Medical Ethics Commissions in the Federal Republic of Germany. In 2000, he was awarded the Paul Martini Prize of the German Society of Medical computer science, Biometry and Epidemiology, Dr. Hasford has also published numerous articles and serves as an editor for Pharmacoepidemiology and Drug Safety publication.

    To view Dr. Joerg Hasford's publications, visit PubMed

    Are you Dr. Joerg Hasford? Send us a message to review your photo and bio, and find out how to submit Creator Insights!
    MDCalc loves calculator creators – researchers who, through intelligent and often complex methods, discover tools that describe scientific facts that can then be applied in practice. These are real scientific discoveries about the nature of the human body, which can be invaluable to physicians taking care of patients.
    Content Contributors
    Reviewed By
    • Michael Mauro, MD
    About the Creator
    Dr. Joerg Hasford
    Are you Dr. Joerg Hasford?
    Content Contributors
    Reviewed By
    • Michael Mauro, MD